{"editorial":{"content_id":"a3ddf303-3f80-4b21-b971-68d973f0d9f3","slug":"anvisa-botox-20261116-266762","content_type":"news","title":"巴西Anvisa批准Botox新适应症，用于治疗成人咬肌肥大","summary":"巴西国家卫生监督局批准Botox（A型肉毒杆菌毒素）新治疗适应症，用于成人良性咬肌肥大。","body":"巴西国家卫生监督局（Anvisa）于11月16日（星期一）批准Botox（A型肉毒杆菌毒素）的新治疗适应症，该产品现可用于治疗成人咬肌显著及非常显著的突出（良性咬肌肥大）。\n\n据Anvisa说明，A型肉毒杆菌毒素通过暂时阻断神经末梢乙酰胆碱的释放发挥作用，从而使治疗部位肌肉局部放松。该药物在巴西已有多项获批的治疗适应症，涵盖神经和肌肉疾病以及美容用途。\n\n咬肌突出（良性咬肌肥大）表现为负责咀嚼的肌肉体积增大，可能导致面部轮廓改变，尤其是下面部区域增宽。该状况虽不危及生命，但可能造成功能性和美观性影响，波及患者的生活质量和自我认知。\n\n新适应症的有效性和安全性证据来自一项评估377人的3期临床试验。结果显示，51.2%接受Botox治疗的参与者在咬肌突出评估量表上达到至少两个等级的改善，而接受安慰剂的参与者中这一比例为2.2%。\n\n相关决议为第4.459/2026号，已在《联邦官方公报》（DOU）上公布。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-11-16T17:01:18.158Z","display_date":"2026-11-16","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-nova-indicacao-terapeutica-para-o-botox","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-botox-20261116-266762","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-botox-20261116-266762","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-botox-20261116-266762?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-botox-20261116-266762?view=json","last_updated":"2026-11-16T17:01:43.033Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}